vs
SUPERIOR GROUP OF COMPANIES, INC.（SGC）与Vericel Corp（VCEL）财务数据对比。点击上方公司名可切换其他公司
SUPERIOR GROUP OF COMPANIES, INC.的季度营收约是Vericel Corp的1.6倍（$146.6M vs $92.9M），Vericel Corp净利率更高（25.0% vs 2.4%，领先22.7%），Vericel Corp同比增速更快（23.3% vs 0.8%），SUPERIOR GROUP OF COMPANIES, INC.自由现金流更多（$17.9M vs $12.8M），过去两年Vericel Corp的营收复合增速更高（34.6% vs 2.7%）
舒必利尔集团（Superior Coach）曾是美国汽车工业的车身制造商，其前身加尔福德卡车公司成立于1909年。该企业最为人熟知的业务是打造灵车等专业车辆车身以及校车车身。受1970年代末两大业务板块的严重衰退影响，公司于1980年被母公司清算，1925年至1980年间，企业总部设于俄亥俄州利马市。
Vericel Corp是一家美国上市生物制药企业，前身为1989年在密歇根州安娜堡成立的Aastrom Bio，2014年10月正式更为现名，专注于生物制药相关领域的研发与商业化运营。
SGC vs VCEL — 直观对比
营收规模更大
SGC
是对方的1.6倍
$92.9M
营收增速更快
VCEL
高出22.5%
0.8%
净利率更高
VCEL
高出22.7%
2.4%
自由现金流更多
SGC
多$5.1M
$12.8M
两年增速更快
VCEL
近两年复合增速
2.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $146.6M | $92.9M |
| 净利润 | $3.5M | $23.2M |
| 毛利率 | 36.9% | 78.7% |
| 营业利润率 | 2.8% | 24.1% |
| 净利率 | 2.4% | 25.0% |
| 营收同比 | 0.8% | 23.3% |
| 净利润同比 | 65.8% | 17.3% |
| 每股收益（稀释后） | $0.23 | $0.46 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收SGCVCEL
| Q4 25 | $146.6M | $92.9M | ||
| Q3 25 | $138.5M | $67.5M | ||
| Q2 25 | $144.0M | $63.2M | ||
| Q1 25 | $137.1M | $52.6M | ||
| Q4 24 | $145.4M | $75.4M | ||
| Q3 24 | $149.7M | $57.9M | ||
| Q2 24 | $131.7M | $52.7M | ||
| Q1 24 | $138.8M | $51.3M |
净利润SGCVCEL
| Q4 25 | $3.5M | $23.2M | ||
| Q3 25 | $2.7M | $5.1M | ||
| Q2 25 | $1.6M | $-553.0K | ||
| Q1 25 | $-758.0K | $-11.2M | ||
| Q4 24 | $2.1M | $19.8M | ||
| Q3 24 | $5.4M | $-901.0K | ||
| Q2 24 | $600.0K | $-4.7M | ||
| Q1 24 | $3.9M | $-3.9M |
毛利率SGCVCEL
| Q4 25 | 36.9% | 78.7% | ||
| Q3 25 | 38.3% | 73.5% | ||
| Q2 25 | 38.4% | 73.7% | ||
| Q1 25 | 36.8% | 69.0% | ||
| Q4 24 | 37.1% | 77.6% | ||
| Q3 24 | 40.4% | 71.9% | ||
| Q2 24 | 38.5% | 69.5% | ||
| Q1 24 | 39.8% | 68.9% |
营业利润率SGCVCEL
| Q4 25 | 2.8% | 24.1% | ||
| Q3 25 | 2.3% | 5.1% | ||
| Q2 25 | 1.3% | -3.2% | ||
| Q1 25 | -0.7% | -24.3% | ||
| Q4 24 | 1.7% | 24.5% | ||
| Q3 24 | 4.4% | -4.3% | ||
| Q2 24 | 0.5% | -11.5% | ||
| Q1 24 | 3.3% | -10.7% |
净利率SGCVCEL
| Q4 25 | 2.4% | 25.0% | ||
| Q3 25 | 2.0% | 7.5% | ||
| Q2 25 | 1.1% | -0.9% | ||
| Q1 25 | -0.6% | -21.4% | ||
| Q4 24 | 1.4% | 26.3% | ||
| Q3 24 | 3.6% | -1.6% | ||
| Q2 24 | 0.5% | -8.9% | ||
| Q1 24 | 2.8% | -7.5% |
每股收益（稀释后）SGCVCEL
| Q4 25 | $0.23 | $0.46 | ||
| Q3 25 | $0.18 | $0.10 | ||
| Q2 25 | $0.10 | $-0.01 | ||
| Q1 25 | $-0.05 | $-0.23 | ||
| Q4 24 | $0.12 | $0.40 | ||
| Q3 24 | $0.33 | $-0.02 | ||
| Q2 24 | $0.04 | $-0.10 | ||
| Q1 24 | $0.24 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $23.7M | $137.5M |
| 总债务越低越好 | $94.1M | — |
| 股东权益账面价值 | $192.8M | $354.6M |
| 总资产 | $421.8M | $488.0M |
| 负债/权益比越低杠杆越低 | 0.49× | — |
8季度趋势，按日历期对齐
现金及短期投资SGCVCEL
| Q4 25 | $23.7M | $137.5M | ||
| Q3 25 | $16.7M | $135.4M | ||
| Q2 25 | $21.0M | $116.9M | ||
| Q1 25 | $19.8M | $112.9M | ||
| Q4 24 | $18.8M | $116.2M | ||
| Q3 24 | $18.4M | $101.7M | ||
| Q2 24 | $13.4M | $102.5M | ||
| Q1 24 | $22.0M | $110.6M |
总债务SGCVCEL
| Q4 25 | $94.1M | — | ||
| Q3 25 | $100.0M | — | ||
| Q2 25 | $99.3M | — | ||
| Q1 25 | $95.7M | — | ||
| Q4 24 | $86.0M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益SGCVCEL
| Q4 25 | $192.8M | $354.6M | ||
| Q3 25 | $193.8M | $321.9M | ||
| Q2 25 | $192.1M | $306.8M | ||
| Q1 25 | $194.4M | $295.5M | ||
| Q4 24 | $198.9M | $292.0M | ||
| Q3 24 | $199.5M | $257.5M | ||
| Q2 24 | $200.9M | $243.0M | ||
| Q1 24 | $200.8M | $233.9M |
总资产SGCVCEL
| Q4 25 | $421.8M | $488.0M | ||
| Q3 25 | $415.3M | $453.3M | ||
| Q2 25 | $423.3M | $435.6M | ||
| Q1 25 | $411.0M | $424.6M | ||
| Q4 24 | $415.1M | $432.7M | ||
| Q3 24 | $407.4M | $390.4M | ||
| Q2 24 | $400.3M | $376.8M | ||
| Q1 24 | $408.5M | $356.7M |
负债/权益比SGCVCEL
| Q4 25 | 0.49× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 0.43× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.4M | $15.0M |
| 自由现金流经营现金流 - 资本支出 | $17.9M | $12.8M |
| 自由现金流率自由现金流/营收 | 12.2% | 13.8% |
| 资本支出强度资本支出/营收 | 0.4% | 2.4% |
| 现金转化率经营现金流/净利润 | 5.32× | 0.65× |
| 过去12个月自由现金流最近4个季度 | $15.8M | $24.7M |
8季度趋势，按日历期对齐
经营现金流SGCVCEL
| Q4 25 | $18.4M | $15.0M | ||
| Q3 25 | $-1.7M | $22.1M | ||
| Q2 25 | $4.9M | $8.2M | ||
| Q1 25 | $-2.0M | $6.6M | ||
| Q4 24 | $8.9M | $22.2M | ||
| Q3 24 | $8.2M | $10.2M | ||
| Q2 24 | $6.9M | $18.5M | ||
| Q1 24 | $9.4M | $7.2M |
自由现金流SGCVCEL
| Q4 25 | $17.9M | $12.8M | ||
| Q3 25 | $-2.4M | $19.5M | ||
| Q2 25 | $3.3M | $81.0K | ||
| Q1 25 | $-3.1M | $-7.6M | ||
| Q4 24 | $7.4M | $8.5M | ||
| Q3 24 | $7.3M | $-9.2M | ||
| Q2 24 | $5.6M | $1.8M | ||
| Q1 24 | $8.8M | $-6.8M |
自由现金流率SGCVCEL
| Q4 25 | 12.2% | 13.8% | ||
| Q3 25 | -1.7% | 28.8% | ||
| Q2 25 | 2.3% | 0.1% | ||
| Q1 25 | -2.3% | -14.5% | ||
| Q4 24 | 5.1% | 11.2% | ||
| Q3 24 | 4.9% | -15.9% | ||
| Q2 24 | 4.2% | 3.4% | ||
| Q1 24 | 6.3% | -13.3% |
资本支出强度SGCVCEL
| Q4 25 | 0.4% | 2.4% | ||
| Q3 25 | 0.5% | 3.9% | ||
| Q2 25 | 1.1% | 12.9% | ||
| Q1 25 | 0.8% | 27.0% | ||
| Q4 24 | 1.0% | 18.3% | ||
| Q3 24 | 0.6% | 33.5% | ||
| Q2 24 | 1.0% | 31.8% | ||
| Q1 24 | 0.5% | 27.3% |
现金转化率SGCVCEL
| Q4 25 | 5.32× | 0.65× | ||
| Q3 25 | -0.61× | 4.35× | ||
| Q2 25 | 3.18× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 4.28× | 1.12× | ||
| Q3 24 | 1.52× | — | ||
| Q2 24 | 11.42× | — | ||
| Q1 24 | 2.41× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
SGC
| Branded Products | $96.9M | 66% |
| Healthcare Apparel | $28.8M | 20% |
| Contact Centers | $21.7M | 15% |
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
